Reported Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine in Jordan
Bibliographic record
Abstract
Background The expediency in producing and approving vaccines for the COVID-19 pandemic is unprecedented. Regrettably, this fomented public distrust and misinformation about vaccination. The Pfizer-BioNTech mRNA-based vaccine was the first to be approved for mass use after phase 3 clinical trials affirmed its safety and efficacy. Vaccine safety monitoring is ongoing. Objective This study aims to describe reported adverse events following immunization with the Pfizer-BioNTech vaccine among first recipients in Jordan. Methods A retrospective descriptive study was conducted on data extracted from the Ministry of Health’s database for the National Vaccine Adverse Event Reporting System from January to May 2021. The frequency of adverse events was compared between the first and second doses and across age groups, gender, and comorbidities. The chi-square test was used to compare categorical variables. Results In total 1874 individuals who received both doses of the vaccine were studied. The mean age was 68 years, with a 2:1 male to female ratio and 73% with comorbidities. About two-thirds (68%) of recipients reported side effects after the first dose, 54.3% after the second, and 53.3% after both. Most common side effects following each and both doses were pain at the injection site (32%), fatigue (16%), and headache (8%), followed by fever, myalgia, and arthralgia. Overall, reported side effects increased 1.4 times after the second dose mostly for systemic side effects. Significantly, more females reported side effects than males, while those with comorbidities reported comparatively fewer side effects (52.2%) than the medically free (59%). Further, 72.5% of recipients aged 55 years or younger reported side effects compared to 50% of older recipients. No anaphylactic reactions were reported. Severe side effects were rare and self-limiting, including tachycardia (n=4), shortness of breath (n=28), and lower limb paresthesia (n=6). Conclusions The Pfizer-BioNTech vaccine has proven to be safe and well tolerated among vulnerable recipients with comorbidities. Continuous adverse event surveillance and follow-up are recommended.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.005 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".